Supply updates

Last updated 30 April 2019

We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.

Supply update for measles, mumps, rubella and varicella-containing vaccines

Priorix-Tetra

GSK will experience a supply constraint of its measles, mumps, rubella & varicella (MMRV) combination vaccine, Priorix Tetra, from the beginning of May to the end of October 2019.

This shortage will impact our ability to supply Priorix Tetra to the National Immunisation Program (NIP) and to non-government customers. GSK has worked with the Commonwealth Department of Health to ensure that an alternative MMRV vaccine will be available during this time, ensuring no impact to children’s immunisations as part of the NIP.

Priorix

GSK is also currently experiencing a supply constraint of its measles, mumps and rubella (MMR) combination vaccine, Priorix, for non-government customers until 1 October 2019 due to provision of vaccine to measles outbreak control programs in a number of states and territories. This constraint does not affect the supply of Priorix to the NIP.

 

Rabies vaccine

GSK is experiencing a supply constraint of its rabies vaccine, Rabipur (inactivated rabies virus vaccine). This supply constraint is due to operational factors and is not related to vaccine quality or safety.

This shortage impacts those who wish to purchase Rabipur for pre-exposure vaccination. For example; those travelling to high rabies risk countries.

GSK understands that all State and Territory Health Departments stockpile rabies vaccines (including Rabipur) for post-exposure prophylaxis (for those individuals who have received an animal wound and considered to be at risk of rabies). We are working with the States and Territories who stock Rabipur to maintain emergency post-exposure stockpiles.

Anyone who needs access to a rabies vaccine should contact their healthcare professional.

 

Hepatitis-containing vaccines

GSK is experiencing supply constraints of the below hepatitis-containing vaccines. These supply constraints are due to manufacturing capacity and are not related to vaccine quality or safety.

  • Havrix Junior - inactivated hepatitis A virus vaccine
  • Twinrix Adult - combined hepatitis A and hepatitis B vaccine
  • Twinrix Junior - combined hepatitis A and hepatitis B vaccine

Supply of GSK’s hepatitis-containing vaccines to Government programs are not impacted.

Please note, the following GSK hepatitis containing vaccines continue to be in stock.

  • Engerix B Adult - hepatitis B surface antigen recombinant (yeast) vaccine
  • Engerix B Paediatric hepatitis B surface antigen recombinant (yeast) vaccine
  • Havrix Adult - inactivated hepatitis A virus vaccine

We expect to provide the next update in July 2019.

 

Herpes zoster vaccine

GSK’s herpes zoster vaccine, Shingrix, is not available in Australia. There is currently no confirmed timing for the supply of Shingrix to Australia.

 

Ventolin (salbutamol sulfate) 5mg/2.5mL nebules

GSK is experiencing a supply constraint of its Ventolin 5mg nebules. This is due to high global demand for the product, with local demand also increasing due to an alternative brand of salbutamol inhalation ampoules being out of stock in Australia. We anticipate intermittent supply throughout 2019. 

This supply constraint does not affect other Ventolin products, including Ventolin Metered Dose Inhalers (also known as ‘puffers’) which continue to be in supply.

 

Please visit the TGA website for ongoing updates to supply.

For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.